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Abstract Mitochondrial neuro-gastro-intestinal encephalo-
myopathy (MNGIE) is a rare and unavoidably fatal disease
due to mutations in thymidine phosphorylase (TP). Clinically
it is characterized by gastrointestinal dysfunction, malnutri-
tion/cachexia and neurological manifestations. MNGIE
diagnosis remains a challenge mainly because of the com-
plexity and rarity of the disease. Thus, our purposes were to
promote a better knowledge of the disease in Emilia-Ro-
magna region (ERR) by creating an accurate and dedicated
network; to establish the minimal prevalence of MNGIE in
Italy starting from ERR. Blood TP activity level was used as
screening test to direct candidates to complete diagnostic
work-up. During the study period of 1 year, only 10/71 units
of ERR recruited 14 candidates. Their screening did not show
TP activity changes. An Italian patient not resident in ERR
was actually proved to have MNGIE. At the end of study in
Italy there were nine cases of MNGIE; thus, the Italian
prevalence of the disease is *0.15/1,000,000 as a gross
estimation. Our study confirms that MNGIE diagnosis is a
difficult process which reflects the rarity of the disease and,
as a result, a low level of awareness among specialists and
physicians. Having available novel therapeutic options (e.g.,
allogenic hematopoietic stem cell transplantation and, more
recently, liver transplantation) and an easy screening test, an
early diagnosis should be sought before tissue damage occurs
irreversibly.
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Introduction
Mitochondrial neuro-gastro-intestinal encephalomyopathy
(MNGIE) is a rare autosomal recessive disease due to
mutations in nuclear TYMP gene, leading to a marked
reduction/absence of the encoded thymidine phosphorylase
(TP) enzyme. As a result, nucleosides [thymidine (dThd)
and deoxyuridine (dUrd)] accumulate and exert a toxic
effect with subsequent mitochondrial DNA damage [1].
The clinical picture is mainly characterized by gastroin-
testinal (GI) dysfunction with frequent intestinal sub-oc-
clusive episodes, malnutrition, cachexia and neurological
involvement including ptosis and ophthalmoparesis,
peripheral neuropathy, myopathy, leukoencephalopathy
[2]. The outcome of the syndrome is fatal and death occurs
usually before the age of 40 years, although mild/atypical
phenotypes have been reported [3]. There are no estab-
lished therapeutic options for patients with MNGIE. Cur-
rently, the most effective treatment is the allogenic
hematopoietic stem cell transplantation (AHSCT), which
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restores persistently TP activity and reduces circulating
toxic levels of dThd and dUrd. However, the clinical
impact of AHSCT is hampered by a high mortality rate and
the need of a highly compatible donor [4].
MNGIE diagnosis remains a clinical challenge often
misunderstood or confused with completely different con-
ditions, e.g., anorexia nervosa and inflammatory bowel
disease (IBD). Apart from its clinical complexity, MNGIE
is often unrecognized mainly because is an extremely rare
disorder. In Europe, the prevalence of this mitochondrial
disorder has been estimated to be *1/1,000,000 people
(http://www.orphanet.it, May 2014), but no previous for-
mal study on its prevalence has been ever performed. Thus,
our goals were to promote a better knowledge of the dis-
ease in the Emilia-Romagna region (ERR), a region of
Northern Italy, by creating an accurate and dedicated net-
work and using TP enzymatic activity as diagnostic marker
[5]. Furthermore, we aimed at establishing the minimal
prevalence of MNGIE in Italy, starting from ERR.
Materials and methods
We performed a formal two-phase study in the ERR and a
non-formal study based on case searching throughout Italy.
ERR study
From 1/11/2013 to 31/10/2014 we contacted all units of
neurology (n = 18, 138 neurologists), gastroenterology
(n = 20, 105 gastroenterologists), pediatric neurology
(n = 19, 69 pediatric neurologists) and eating behavior
disorders (EBS)/psychiatry (n = 14, 52 psychiatrics) of the
ERR (4,457,115 inhabitants as of 31/12/2014) to record any
possible case of MNGIE according to the following includ-
ing criteria: presence of severe gastrointestinal dysfunction
(chronic symptoms affecting patient’s quality of life to
impair a normal life and/or inducing absenteeism fromwork)
or malnutrition/weight loss or suspected anorexia nervosa;
with/without of neurological signs (e.g., sensory-motor
peripheral neuropathy, deafness, ptosis/ophtalmoparesis)
(Table 1). A summary of MNGIE symptoms was sent to
physicians followed by a personal phone/mail reminder
every 2 months. A blood sample (10 mL in EDTA) was
obtained from each candidate samples were used to isolate
the buffy coat in order to measure lymphocyte TP activity
quantified by the rate of conversion of dThd to thymine.
Patients with TP activity levels\252 nmol/h mg [5] com-
pleted the diagnostic work-up, i.e. EMG, brain MRI, muscle
biopsy, and TYMP sequences analysis to confirm MNGIE
diagnosis. The study was approved by the ethic committees
of all participating centers of the ERR and all patients gave
their informed consent to the inclusion.
Search for MNGIE cases in Italy
Italian ‘‘extra-ERR’’ resident patients fulfilling the inclusion
criteria and examined in the aforementioned units were
tested. Moreover, we contacted all genetic centers in Italy
enquiring about MNGIE cases still alive as of 30/11/2014.
Results
Among the 71 units involved, only 5 neurology, 4 gas-
troenterology, and 1 pediatric neurology centers recruited
candidates for TP activity screening. No candidates were
identified by EBS/psychiatry units. A total of 30 patients
were tested, i.e. 19, 8, and 3, referred by neurologists,
gastroenterologists, and pediatric neurologists,
respectively.
ERR study
During the study period, 14 ERR resident cases of sus-
pected MNGIE were included (Table 1). All patients had
TP activity levels within normal range (332–1580 nmol/
h mg; normal value[252).
Table 1 Inclusion criteria/clinical features of 14 ‘‘ERR patients’’
screened for MNGIE: 14 subjects (7 M ? 7 F), mean age
40.8 ± 11.5 years (range 22–55), mean BMI 18.1 ± 3.1 kg/m2
(range 16–24)
n (%)
Gastrointestinal (1 or more)a
Malnutrition
Weight loss 14 (100 %)
Cachexia 3 (21 %)
Severe gastrointestinal dysfunction
Early satiety 13 (93 %)
Postprandial distension 12 (86 %)
Abdominal cramps 11 (79 %)
Abdominal borborygmi 10 (71 %)
Sub-occlusive episodes 9 (64 %)
Nausea 8 (57 %)
Gut surgery 7 (50 %)
Vomiting 5 (36 %)
Suspected anorexia nervosa 0 (0 %)
Neurologicalb
Neuropathy 7 (50 %)
Opthalmopharesis 5 (36 %)
Ptosis 2 (14 %)
Deafness 2 (14 %)
a Mandatory
b Optional
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Extra-ERR study
Sixteen extra-ERR resident patients were tested and one of
these with low TP activity level (4 nmol/h mg) was
eventually confirmed to have MNGIE by genetic test.
Notably, this patient was misdiagnosed as an IBD and
managed for 3 years with immunosuppressive agents.
As of 30/11/2014 there were nine established cases of
MNGIE recorded in Genetic Centers in Italy, a Country
with 59,464,644 inhabitants (2011 census). Thus, the Ital-
ian prevalence of MNGIE is *0.15/1,000,000 as a gross
estimation.
Discussion
Despite an accurate and dedicated network, based on
individual periodical contacts with different specialists, we
could not identify any case of MNGIE in the ERR, a
finding reflecting the rarity of such condition and, possibly,
the difficulty to diagnose it. Therefore we cannot rule out
the possibility that some patients with MNGIE has not been
conveniently recognized in the ERR network despite our
efforts. In this line, the number of patients screened was
considerably lower than expected on the basis of the
anorexia nervosa prevalence (0.3 and 0.03 % for females
and males, respectively, aged 15–24, accounting for 606
estimated patients in the ERR) [6], a known misdiagnosis
of MNGIE. The reason why no candidates were screened
from the EBS/psychiatric units of ERR remains unknown
and may reflect a lower level of awareness of these spe-
cialists about MNGIE. This is a crucial issue since the
misdiagnosis of patients with MNGIE may lead to a sig-
nificant delay of possible currently available therapeutic
solutions, i.e. AHSCT [4] or, more recently, liver trans-
plantation [7, 8] aimed to restore permanently TP. The
extra-ERR MNGIE patient, identified during this study,
was successfully treated for the first time with liver trans-
plantation. His clinical conditions and biochemical data are
satisfactory at 8 months of follow-up [8].
Our survey further indicates that MNGIE is an extre-
mely rare disease with a prevalence in Italy of *0.15/
1,000,000, lower than that indicated by Orphanet, probably
due to overestimation by assessing published cases rather
than through case finding, or alternatively, we have
underestimated MNGIE.
In conclusion, having available novel therapeutic
options (AHSCT or liver transplantation) and the possi-
bility to rely to a relatively easy screening test (TP activity
assay), specialists and physicians in general should recog-
nize conveniently patients with MNGIE in order to achieve
an early diagnosis and treat patients before tissue damage
occurs irreversibly.
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